Printer Friendly

Experts present first recommendations for treating acne fulminans.

SCOTTSDALE, ARIZ. -- Patients with acne fulminans should first begin corticosteroid monotherapy before adding isotretinoin, according to the first evidence-based consensus recommendations on this disease.

Antibiotics should not be used as first line treatment or monotherapy for acne fulminans, according to the experts who drafted the recommendations. Acne fulminans is an uncommon, understudied, and severe disorder that "typically manifests as an explosive worsening and ulceration of skin lesions and can be associated with fever, bone pain, and other systemic symptoms," noted panel cochairs Dr. Andrea Zaenglein, professor of dermatology and pediatric dermatology, Pennsylvania State University, Hershey, and Dr. Sheila Friedlander, professor of medicine and pediatrics, University of California, San Diego, together with their associates.

The recommendations--based on a full literature review, a 5-hour audio-conference, and two rounds of surveys to achieve consensus on these topics were summarized in a poster presented at the annual meeting of the Society for Investigative Dermatology.

Until now, there have been no clear guidelines on the pathogenesis, treatment, and prevention of acne fulminans, according to the panelists.

Consensus definitions

Acne fulminans is not just an extreme form of acne but, rather, a distinct, likely auto-inflammatory, disorder," the experts stated. Affected patients typically have an "abrupt, dramatic flare of inflammatory acne, with erosions and with or without crusts, hemorrhagic nodules/plaques, and systemic findings."


Systemic involvement is uncommon, but, when present, includes fever, malaise, bone pain, arthralgias, erythema nodosum, and leukocytosis, they noted. Some patients also have anemia, an elevated erythrocyte sedimentation rate, and an increased C-reactive protein level. Radiography typically reveals osteolytic lesions of the sternum, clavicles, sacroiliac joints, and hips.

Acne fulminans is most often triggered by isotretinoin therapy but can occur without it, the panel said. Isotretinoin-induced acne fulminans can have systemic involvement, but usually does not.


Patients should start corticosteroid monotherapy at a dose of 0.5 to 1.0 mg per kg per day, according to the recommendations. Patients with systemic involvement should receive steroids for at least 4 weeks, and other patients should continue steroids for at least 2 weeks and until all lesions have healed.


Oral corticosteroids should be tapered slowly over about 4 to 8 weeks, first by halving the dose to a physiologic dose each week, and then by dosing every other day for 2 weeks.

Topical corticosteroids also can be used for eroded sites with granulation tissue, they noted.


Ironically, isotretinoin is both a treatment and a potential trigger of acne fulminans, and the recommendations included detailed guidance on its use.

Patients should wait at least 2 weeks after crusting resolves before starting isotretinoin and should overlap isotretinoin with corticosteroids for at least 4 weeks, the experts emphasized. They recommended starting isotretinoin at 0.1 mg per kg per day and waiting at least 2 months to increase this dose. Because patients clear at different rates, there is no universal optimal cumulative dose of isotretinoin, they noted.

If patients on isotretinoin develop flare, crusts, and erosions, they should halt treatment and either start corticosteroids or increase the steroid dose to 1.0 mg per kg. If crusts and erosions persist, the panelists recommended considering cyclosporine, biologies, or dapsone.

If hemorrhagic crusts or erosions resolve after stopping isotretinoin, it can be restarted at the initial dose of 0.1 mg per kg and overlapped with steroids for 4 weeks.

If flares, crusts, and erosions begin when patients on isotretinoin are tapering corticosteroids, then steroids should be continued without tapering, isotretinoin should be stopped temporarily, and it should be restarted at 0.1 mg per kg after crusts and erosions have healed. This dose should be continued for 4 weeks then slowly increased as tolerated.


Antibiotics are not useful as monotherapy for first-line therapy for acne fulminans, according to the recommendations. But, to avoid isotretinoin-induced acne fulminans, the experts often pretreat patients with oral antibiotics before starting isotretinoin and may continue oral antibiotics during the initial phase of isotretinoin treatment. However, there have been no prospective studies supporting this approach, they noted.

Other treatment considerations

Acne fulminans lesions should not be debrided, the experts emphasized. Acne fulminans associated with SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis), PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne), and PA PASH (pyogenic arthritis, pyoderma gangrenosum, acne, and hydradenitis suppurativa) has responded successfully to tumor necrosis factor-alpha inhibitors and interleukin-1 receptor antagonists, they noted. Pulsed dye laser also has been used to successfully treat acne fulminans, particularly when there is associated granulation tissue, they stated.

Reducing the risk of pseudotumor cerebri syndrome

Several drugs used to treat acne fulminans have been linked to pseudotumor cerebri syndrome, the experts cautioned. "Among the tetracyclines, minocycline carries the highest risk," they noted. Both isotretinoin and corticosteroids have been linked to pseudotumor cerebri syndrome, but clinicians can reduce this risk by avoiding an abrupt steroid taper, they emphasized.

The panel included physicians from the University of California, San Diego; Pennsylvania State University, Hershey; State University of New York, Brooklyn; Cornell University, New York; Touro University California, Vallejo; the University of California, San Francisco; the University of Pennsylvania, Philadelphia; and Jefferson Medical College, Philadelphia. They did not disclose conflicts of interest.


* Managing acne fulminans requires a delicate approach with powerful medicines.

One thing that makes managing acne fulminans so challenging is that the very medication we use to treat it (Isotretinoin), is also the most common trigger of the disorder. Many of us have witnessed the tragic explosion of acne with crusting and even systemic symptoms after initiating a course of Isotretinoin. What do you do when the best treatment we have for severe acne is igniting a serious flare? Thanks to Dr. Zaenglein and Dr. Friedlander, we now have evidence-based recommendations to guide us.

First of all, If acne fulminans arises after starting isotretinoin, then isotretinoin must be discontinued until the Inflammation and crusting have subsided. Treat with oral corticosteroids for at least 2-4 weeks, until crusting has resolved. About 2 weeks after resolution of crusting, isotretinoin can then be added to the regimen beginning at 0.1mg/kg per day and overlapped with corticosteroids for at least 4 weeks. It is recommended that the isotretinoin should not be Increased for at least 2 months. Traditional recommendations for cumulative doses may not apply In acne fulminans.

Effectively navigating through a course of acne fulminans requires that we heed the advice to "start low and go slow." Unfortunately, the novice isotretinoin user might be tempted to keep pushing the dose higher and higher, which is the wrong approach. Baby steps, one step at a time, easy does it is the best approach to prescribing isotretinoin in acne fulminans.



Caption: Dr. Sheila Fallon Friedlander

Caption: Dr. Andrea Zaenglein
COPYRIGHT 2017 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Karon, Amy
Publication:Dermatology News
Date:Jul 1, 2017
Previous Article:Study identifies link between rosacea and several GI disorders.
Next Article:For optimal care, consider all acne in Latinos inflammatory.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters